The Companies Dominating Mental Health Peptides in 2025
Peptides Move Into Psychiatry’s Spotlight
Peptides have long been familiar to elite performance communities and regenerative medicine clinics. In 2025, they are gaining traction as a functional psychiatry tool — offering potential breakthroughs for anxiety, depression, and neuro-regulation. While the research remains emergent, a growing cluster of companies is shaping the commercial landscape, pairing peptides with digital platforms and clinical delivery models.
Key Players in Mental Health Peptides
1. Nootropic Peptide Pioneers — Nootrobox/Health Via Modern Nutrition (HVMN)
Focus: Originally positioned as a nootropics company, HVMN has expanded its research into peptides like Semaxand Selank, citing early studies linking them to reduced anxiety and improved focus.
Business Model: Consumer-grade supplements, paired with educational platforms for biohackers and professionals.
Reach: Millions of downloads on their podcast and a strong foothold in Silicon Valley’s performance-driven culture.
2. Next Health (U.S.)
Focus: A high-end functional medicine and longevity clinic with locations in Los Angeles, NYC, and Miami.
Peptide Integration: Offers BPC-157, Thymosin Alpha-1, and other compounds as part of its optimization protocols. Increasingly, peptides are paired with mood and resilience programs, framing them as “adjacent psychiatry.”
Market Strategy: Positions itself at the intersection of luxury wellness and integrative psychiatry, drawing clientele from executives and celebrities.
3. Hum2n (London, U.K.)
Focus: Branded as Europe’s most advanced biohacking and longevity clinic.
Peptide Programs: Includes Semax and Selank in tailored “neuro-regulation stacks” aimed at clients with burnout and chronic anxiety.
Funding: Privately backed by U.K.-based wellness investors; rapid expansion in 2024/25 reflects rising consumer demand for functional psychiatry.
4. NADClinic Group (Europe/Middle East)
Focus: Initially positioned around NAD+ IV drips, the group has expanded into peptides for mood stabilization and neuro-repair.
Reach: Operating in London, Dubai, and Geneva, with plans for New York entry.
Peptide Positioning: Targets high-net-worth clientele seeking alternatives to long-term psychiatric medications.
5. Biotech Entrants — Reviva Pharmaceuticals & MindMed (early explorations)
Reviva Pharmaceuticals: Announced exploratory programs into peptide-based compounds for neuropsychiatric conditions, including schizophrenia and depression.
MindMed: While best known for psychedelics, MindMed is exploring adjacent peptide-based therapies that modulate serotonin receptors.
Market Impact: These companies bring biotech credibility to what was previously an unregulated space.
The Research Base
Semax & Selank: Clinical history in Russia as anxiolytic and nootropic agents, with small-scale studies showing improvements in anxiety and cognitive function.
BPC-157: Animal studies suggest neuroprotective effects, though human trials are limited.
Thymosin Alpha-1: Being evaluated for immune modulation and resilience, indirectly tied to psychiatric wellbeing.
Market Dynamics in 2025
User Base: Concentrated among high-income professionals, biohackers, and early adopters of concierge medicine. Estimates place the global peptide therapy market at $2.2B in 2025, with mental health applications representing a growing share.
Funding: Clinics like Next Health and Hum2n are attracting venture interest in the $10M–$30M range, reflecting demand for scalable models in functional psychiatry.
Regulation: Remains fragmented. In the U.S., most peptides are prescribed off-label through compounding pharmacies. Europe offers slightly more formal oversight, though access is still niche.
27K Ventures Take
The companies dominating the mental health peptide space are not purely pharmaceutical players — they are integrative clinics and wellness platforms, building trust with consumers who want alternatives to long-term psychiatric drugs. Their advantage lies in branding and delivery as much as in science.
At 27K Ventures, we believe the winners will be those who:
Pair science with accessibility, ensuring peptides move beyond luxury wellness into broader psychiatric adoption.
Build credibility through clinical trials while maintaining design-forward, consumer-friendly interfaces.
Balance ethics with innovation, preventing a repeat of past “miracle cure” cycles.
Peptides in psychiatry remain an emerging but compelling bet. Investors and founders alike should watch the companies that can transform this early wave into a validated, scalable category — not just for the elite, but for the millions navigating anxiety and stress worldwide.